Difference between revisions of "Evox Therapeutics Limited Patent Application Trends in 2024"
Jump to navigation
Jump to search
Wikipatents (talk | contribs) (Updating Evox Therapeutics Limited_Patent_Application_Trends_in_2024) |
Wikipatents (talk | contribs) (Updating Evox Therapeutics Limited_Patent_Application_Trends_in_2024) |
||
| Line 1: | Line 1: | ||
== Evox Therapeutics Limited Patent Filing Activity == | == Evox Therapeutics Limited Patent Filing Activity == | ||
== Evox Therapeutics Limited patent applications in 2024 == | == Evox Therapeutics Limited patent applications in 2024 == | ||
| − | [[File:Evox Therapeutics Limited Monthly Patent Applications 2024 - Up to | + | [[File:Evox Therapeutics Limited Monthly Patent Applications 2024 - Up to September 2024.png|border|800px]] |
== Top 10 Technology Areas == | == Top 10 Technology Areas == | ||
| − | [[File:Evox Therapeutics Limited Top Technology Areas 2024 - Up to | + | [[File:Evox Therapeutics Limited Top Technology Areas 2024 - Up to September 2024.png|border|800px|Evox Therapeutics Limited Top Technology Areas 2024 - Up to September 2024]] |
* [[:Category:CPC_A61K47/6901|A61K47/6901]] ({Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}) | * [[:Category:CPC_A61K47/6901|A61K47/6901]] ({Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}) | ||
| Line 21: | Line 21: | ||
** Example: [[20240197908. MODIFIED EXTRACELLULAR VESICLES (EVS) WITH IMPROVED HALF-LIFE simplified abstract (Evox Therapeutics Limited)]] | ** Example: [[20240197908. MODIFIED EXTRACELLULAR VESICLES (EVS) WITH IMPROVED HALF-LIFE simplified abstract (Evox Therapeutics Limited)]] | ||
== Emerging Technology Areas == | == Emerging Technology Areas == | ||
| − | [[File:Evox Therapeutics Limited Top Emerging Technology Areas 2024 - Up to | + | [[File:Evox Therapeutics Limited Top Emerging Technology Areas 2024 - Up to September 2024.png|border|800px|Evox Therapeutics Limited Top Emerging Technology Areas 2024 - Up to September 2024]] |
* [[:Category:CPC_C12P21/02|C12P21/02]] (having a known sequence of two or more amino acids, e.g. glutathione) | * [[:Category:CPC_C12P21/02|C12P21/02]] (having a known sequence of two or more amino acids, e.g. glutathione) | ||
| Line 39: | Line 39: | ||
** Example: [[20240197908. MODIFIED EXTRACELLULAR VESICLES (EVS) WITH IMPROVED HALF-LIFE simplified abstract (Evox Therapeutics Limited)]] | ** Example: [[20240197908. MODIFIED EXTRACELLULAR VESICLES (EVS) WITH IMPROVED HALF-LIFE simplified abstract (Evox Therapeutics Limited)]] | ||
== Top Inventors == | == Top Inventors == | ||
| − | [[File:Evox Therapeutics Limited Top Inventors 2024 - Up to | + | [[File:Evox Therapeutics Limited Top Inventors 2024 - Up to September 2024.png|border|800px|Evox Therapeutics Limited Top Inventors 2024 - Up to September 2024]] |
* [[:Category:Christopher DAVIES|Christopher DAVIES]] (1 patent) | * [[:Category:Christopher DAVIES|Christopher DAVIES]] (1 patent) | ||
* [[:Category:Justin HEAN|Justin HEAN]] (1 patent) | * [[:Category:Justin HEAN|Justin HEAN]] (1 patent) | ||
* [[:Category:Xiuming LIANG|Xiuming LIANG]] (1 patent) | * [[:Category:Xiuming LIANG|Xiuming LIANG]] (1 patent) | ||
== Patent Categories == | == Patent Categories == | ||
| − | [[File:Evox Therapeutics Limited Patent Categories 2024 - Up to | + | [[File:Evox Therapeutics Limited Patent Categories 2024 - Up to September 2024.png|border|500px|Evox Therapeutics Limited Patent Categories 2024 - Up to September 2024]] |
== Geographical Distribution of Inventors == | == Geographical Distribution of Inventors == | ||
| − | [[File:Evox Therapeutics Limited Inventor Countries 2024 - Up to | + | [[File:Evox Therapeutics Limited Inventor Countries 2024 - Up to September 2024.png|border|800px|Evox Therapeutics Limited Inventor Countries 2024 - Up to September 2024]] |
== Geographical Distribution of US Inventors == | == Geographical Distribution of US Inventors == | ||
| − | [[File:Evox Therapeutics Limited Inventor States 2024 - Up to | + | [[File:Evox Therapeutics Limited Inventor States 2024 - Up to September 2024.png|border|800px|Evox Therapeutics Limited Inventor States 2024 - Up to September 2024]] |
[[Category:Evox Therapeutics Limited]] | [[Category:Evox Therapeutics Limited]] | ||
Latest revision as of 01:59, 20 October 2024
Contents
Evox Therapeutics Limited Patent Filing Activity
Evox Therapeutics Limited patent applications in 2024
Top 10 Technology Areas
- A61K47/6901 ({Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors})
- A61K47/64 (Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers)
- A61K47/643 (Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers)
- C12N5/0662 (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media)
- C12P21/02 (having a known sequence of two or more amino acids, e.g. glutathione)
Emerging Technology Areas
- C12P21/02 (having a known sequence of two or more amino acids, e.g. glutathione)
- C12N5/0662 (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media)
- A61K47/643 (Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers)
- A61K47/64 (Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers)
- A61K47/6901 ({Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors})
Top Inventors
- Christopher DAVIES (1 patent)
- Justin HEAN (1 patent)
- Xiuming LIANG (1 patent)
Patent Categories
Geographical Distribution of Inventors
Geographical Distribution of US Inventors
Evox Therapeutics Limited Inventor States 2024 - Up to September 2024
